These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 2970407)

  • 1. Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.
    Frydman R; Belaisch-Allart J; Parneix I; Forman R; Hazout A; Testart J
    Fertil Steril; 1988 Sep; 50(3):471-5. PubMed ID: 2970407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments.
    Frydman R; Parneix I; Belaisch-Allart J; Forman R; Hazout A; Fernandez H; Testart J
    Hum Reprod; 1988 May; 3(4):559-61. PubMed ID: 2969005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ovarian stimulation for in vitro fertilization using LHRH agonists: comparison of plasma and intra-follicular hormone profiles using "short" and "long" protocols].
    Antoine JM; Firmin C; Alvarez S; Cornet D; Tibi C; Mandelbaum J; Plachot M; Salat-Baroux J
    J Gynecol Obstet Biol Reprod (Paris); 1990; 19(8):1035-40. PubMed ID: 2150525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins.
    Caspi E; Ron-El R; Golan A; Nachum H; Herman A; Soffer Y; Weinraub Z
    Fertil Steril; 1989 Jan; 51(1):95-9. PubMed ID: 2521328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Simulation of ovulation using two types of LH-RH agonists].
    Frydman R; Belaisch-Allart J; Fernandez H; Baton C; Glissant A; Hazout A
    J Steroid Biochem; 1989 Oct; 33(4B):827-9. PubMed ID: 2532271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
    Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
    Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
    Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
    Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine profiles and luteal function during GnRH-analogue/HMG therapy.
    Braendle W; Lindner C; Lichtenberg V; Goepel E; Bettendorf G
    Hum Reprod; 1989 Nov; 4(8 Suppl):121-6. PubMed ID: 2533217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
    Branigan EF; Estes MA
    Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.